Claims for Patent: 5,739,033

Summary for Patent: 5,739,033

Title:	Physiological cell separation and method of separating cells using same
Abstract:	An aqueous composition, initially present as a two-phase gradient, useful for separation of two cell types, such as islet cells from acinar cells, is disclosed, as well as a method of separating the cells. The composition is comprised of a water soluble, metabolically inert substance which maintains density, osmolarity and pH in the presence of cells, and a physiological cold storage solution comprising viscosity modifiers to increase the viscosity and osmotically active impermeant agents for suppressing cold-induced cellular edema, and also comprising a physiological solution capable of maintaining viable cells. These solutions are present in various combinations in a concentration sufficient to provide a first solution with a density greater than both cell types in their natural state, and less than the second cell type after incubation in said solution, and a second solution having a density less than that of both cell types. The system is allowed to stand or is centrifuged to separate the cells.
Inventor(s):	Soon-Shiong; Patrick (Los Angeles, CA)
Assignee:	Vivorx, Inc. (Santa Monica, CA)
Application Number:	08/486,404
Patent Claims:	1. An aqueous density gradient composition for isolating and purifying pancreatic islets from a population of acinar cells, in which the population had been previously exposed to collagenase through pancreatic ductal injection, by introducing said population containing islets and acinar cells to the composition, said composition comprising: (A) a first, or lower solution having a density between 1.097 and 1.126 g/ml, and being slightly hypertonic to the islets and acinar cells, said first solution comprising a mixture of a water soluble, metabolically inert substance selected from 5-(N-2,3-dihydroxypropylacetamido) 2,4,5-tri-iodo-N,N'-bis(2,3-dihydroxypropyl) isophthalamide and Metrizamide.RTM., mixed with a physiological cold storage solution selected from University of Wisconsin (UW) solution and Eurocollins; (B) and a second, or upper solution, having a density of 1.008 g/ml or less, selected from the group consisting of: (1) a physiological solution capable of maintaining viable cells selected from the group consisting of Hank's solution, RPMI, MEM, and Eagle's medium, and (2) a mixture of a water-soluble, metabolically inert substance selected from 5-(N-2,3-dihydroxypropylacetamido) 2,4,5-ti-iodo-N,N'-bis(2,3-dihydroxypropyl) isophthalamide and Metrizamide, mixed with a physiological cold storage solution selected from UW solution and Eurocollins, overlaid with a physiological solution capable of maintaining viable cells, selected from the group consisting of Hank's solution, RPMI, MEM, and Eagle's medium. 2. The composition according to claim 1, wherein said physiological cold storage solution has a viscosity in the range of about 1.5 to about 2.3 mPa. s. 3. The composition according to claim 1, wherein said first and second solutions have osmolarities in the range of about 320 mOsm to about 440 mOsm. 4. A method of isolating pancreatic islets from a population containing acinar cells, wherein the population containing islets and acinar cells had been previously exposed to collagenase through pancreatic ductal injection, said method comprising: (A) adding said population of islets and cells to a first or lower solution, said solution having a density between 1.097 and 1.126 g/ml, and being slightly hypertonic to the islets and acinar cells, comprising a mixture of a water soluble, metabolically inert substance selected from 5-(N-2,3-dihydroxypropylacetamido) 2,4,5-tri-iodo-N,N'-bis(2,3-dihydroxypropyl) isophthalamide and Metrizamide.RTM., mixed with a physiological cold storage solution selected from University of Wisconsin (UW) solution and Eurocollins; (B) layering a second solution, having a density of 1.008 g/ml or less, selected from the group consisting of: (1) a physiological solution capable of maintaining viable cells selected from the group consisting of Hank's solution, RPMI, MEM, and Eagle's medium, and (2) a mixture of a water-soluble, metabolically inert substance selected from 5-(N-2,3-dihydroxypropylacetamido) 2,4,5-ti-iodo-N,N'-bis(2,3-dihydroxypropyl) isophthalamide and Metrizamide, mixed with a physiological cold storage solution selected from UW solution and Eurocollins, overlaid with a physiological solution capable of maintaining viable cells, selected from the group consisting of Hank's solution, RPMI, MEM, and Eagle's medium; (C) separating the two cell types by letting the solution sit at 1 g for least 30 minutes, or by applying a centrifugal force up to about 180 g for about 15 minutes at 4.degree. C., to said combination of solutions whereby said islets collect at or near the interface between said first solution and said second solution and said acinar cells accumulate at or near the bottom below said first solution, and (D) removing said islet cells. 5. The method according to claim 4, wherein said physiological cold storage solution has a viscosity in the range of about 1.5 to about 2.3 mPa. s. 6. The method according to claim 4, wherein said first and second solutions have osmolarities in the range of about 320 mOsm to about 440 mOsm.

Details for Patent 5,739,033

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2015-04-14